Clinical Trials Directory

We are doing this study to compare the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib. We want to find out if adding gilteritinib to the usual treatment is beneficial for people with acute myeloid leukemia (AML).

We are doing this study to find out if 2 different experimental drug combinations can improve outcomes for people who are newly diagnosed with AML. We want to compare the outcomes from the standard treatment (cytarabine + daunorubicin) to the following experimental regimens:

• Venetoclax + cytarabine + daunorubicin
• Venetoclax + azacitidine

We are doing this study to compare different experimental drug regimens to the usual treatment (cytarabine and daunorubicin) for acute myeloid leukemia (AML). We want to find out which options have the best outcomes. The different drug combinations we will be testing against the usual treatment are:

• daunorubicin and cytarabine liposome
• cytarabine and daunorubicin with venetoclax
• azacitidine and venetoclax
• daunorubicin and cytarabine liposome with venetoclax

We are doing this study to see if blood and bone marrow samples can be tested in a timely manner that allows for the detection of certain markers that could guide cancer treatment.

We are using you or your child's medical information in this study to better understand the diagnosis, treatment, and complications of Spina Bifida.

We created the Registry for Brain Health to help you improve your brain health and get involved in research studies. The number of people in North Carolina affected by memory disorders, such as Alzheimer's disease and other forms of dementia, is going up. To change that, we must work together, stay informed, and get involved. We are enrolling both people who have memory problems and people who are healthy and do not have memory problems.

This study has two parts. In the first part, people will be placed into one of two groups by chance. One group will receive a medicine called efimosfermin, and the other group will receive a placebo, which has no active medicine. The medicine is given as a shot every four weeks for about 92 weeks. People who finish the first part may be able to join the second part of the study. In this part, everyone receives efimosfermin every four weeks for about 152 weeks. The study lasts a little over five years. During this time, participants will have many clinic visits and phone contacts. They will have blood tests, liver scans, ultrasound exams, liver biopsies, and questionnaires about their health. Participants will also visit the study center every month to receive the study medicine.

We are doing this study to find out if an investigational called Daromun (the study drug) is a safe and effective treatment for melanoma. We want to know if treating people with the drug before surgery to remove tumors can lower the chance of cancer recurrence.